⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DSGN News
Design Therapeutics, Inc. Common Stock
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
globenewswire.com
DSGN
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
globenewswire.com
DSGN
Form 8-K
sec.gov
DSGN
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
globenewswire.com
DSGN
O Novo World ID: prova de humanidade para a era da IA expande para plataformas digitais que pessoas e empresas usam diariamente
businesswire.com
ZM
DSGN
OKTA
MTCH
The New World ID: Proof of Human for the AI Era Scales Across the Digital Platforms People and Businesses Use Every Day
businesswire.com
ZM
DSGN
OKTA
MTCH
Form 8-K
sec.gov
DSGN
Form 8-K
sec.gov
DSGN
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
globenewswire.com
DSGN
Design Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
DSGN